ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1
ViiV Healthcare is pleased to announce that the U.S. FDA has approved Tivicay® (dolutegravir) 50-mg tablets...
List view / Grid view
News
Amgen and Servier complete product collaboration transaction
12 August 2013 | By Amgen
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement...
METTLER TOLEDO’s weighing standard ensures USP compliance – free on-demand webinar clarifies the new rules
11 August 2013 | By METTLER TOLEDO
On the 3rd June, 2013, USP published the revised mandatory Chapter 41 on balances as well as new updates to the advisory Chapter 1251.
BIOTRAK(TM) real-time viable particle counter
10 August 2013 | By TSI Inc.
The BIOTRAK Particle Counter is a full-featured instrument that detects the total number of particles in the air as well as determines which of those particles are viable in nature...
Novo Nordisk increased operating profit by 15% in the first six months of 2013
8 August 2013 | By Novo Nordisk
Sales growth of 11% driven by Victoza®, NovoRapid® and Levemir®...
Teva receives European Marketing Authorization for Lonquex® (XM22 lipegfilgrastim)
8 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)...
European Commission approves VELCADE® as a frontline induction therapy before stem cell transplantation
8 August 2013 | By Johnson & Johnson
Janssen announced that the European Commission has approved the use of VELCADE® (bortezomib)...
Novartis first company accredited with global “CEO Cancer Gold Standard” for outstanding efforts in cancer prevention and treatment
8 August 2013 | By Novartis
"At Novartis, we believe that everyone should have access to early screening programs and innovative therapies..."
GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
8 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the launch of Action Potential Venture Capital (APVC) Limited...
Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
7 August 2013 | By Novartis
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib...
FT Global Pharmaceutical and Biotechnology Conference
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."
Sanofi Pasteur initiates Phase III study of investigational Clostridium difficile vaccine
5 August 2013 | By Sanofi
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide...
Roche and the Medicines Patent Pool sign agreement to increase access to medicines to treat CMV infection in HIV-patients, a major cause of blindness
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
albiglutide US PDUFA date extended by three months
2 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide has been extended by three months...
